ATR and cancer: Because of the substantial replication stress of cancer cells, ATR is considered an attractive target for anticancer therapy (10, 11) and selective ATR inhibitors that are currently in clinical trials include berzosertib (M6620, VX-970) and elumusertib (BAY-1895344; Table 1).